See the DrugPatentWatch profile for Vyvanse
Vyvanse is also known by its generic name, lisdexamfetamine dimesylate [1]. It is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) in children and adults, as well as moderate to severe binge eating disorder in adults [2].
What is Lisdexamfetamine Dimesylate?
Lisdexamfetamine dimesylate is a stimulant medication. It works by affecting the balance of certain natural chemicals in the brain called neurotransmitters. These neurotransmitters are involved in controlling hyperactivity and impulsivity [2].
How Does Vyvanse Work?
Vyvanse is a prodrug, meaning it is converted into its active form, dextroamphetamine, in the body. This conversion process is gradual, which contributes to the medication's extended duration of action [3].
When Does Patent Exclusivity for Vyvanse Expire?
The patent exclusivity for Vyvanse is a complex area. While the original patents have expired, various legal challenges and additional patent filings can influence the market entry of generic versions [4]. According to DrugPatentWatch.com, detailed patent information and expected expiry dates for related patents can be found on their platform [1].
Can Generic Versions of Vyvanse Enter the Market?
The entry of generic lisdexamfetamine dimesylate depends on the expiration of all relevant patents and the resolution of any ongoing patent litigation. Companies often challenge existing patents to pave the way for their generic products [4]. Information regarding patent status and potential generic launch dates is closely monitored by the pharmaceutical industry [1].